Baptista T, Teneud L, Hernández L
Laboratorio de Fisiología de la Conducta, Facultad de Medicina, Universidad de Los Andes, Mérida, Venezuela.
Pharmacol Biochem Behav. 1993 May;45(1):45-9. doi: 10.1016/0091-3057(93)90083-6.
Long-term administration of sulpiride induces hyperphagia and obesity in female rats. After sulpiride withdrawal, a significant hypophagia has been observed. The hyperphagia could be related to the blockade and the hypophagia to supersensitivity of dopamine D2 receptors, in particular those D2 receptors located in the perifornical hypothalamus. If this were the case, an enhancement of anorexia induced by amphetamine and dopamine should be observed after interruption of long-term sulpiride treatment. Two doses of systemic sulpiride (20 or 200 mg/kg) and one dose of intrahypothalamic sulpiride (15 micrograms) were tested. Amphetamine was administered by systemic or intrahypothalamic infusion. Dopamine was administered in the hypothalamus. After withdrawal of systemic administration of sulpiride (200 mg/kg), an enhancement of anorexia induced by systemic amphetamine was observed. However, the anorexia induced by intrahypothalamic injections of amphetamine or dopamine was not affected by the interruption of the sulpiride treatment. These results suggest that the hypophagia following chronic sulpiride treatment is not due to supersensitivity of D2 dopamine receptors in the lateral hypothalamus. Moreover, the change in the response to amphetamine might be related to supersensitivity of extrahypothalamic D2 receptors.
长期给予舒必利可导致雌性大鼠食欲亢进和肥胖。停用舒必利后,可观察到明显的食欲减退。食欲亢进可能与多巴胺D2受体的阻断有关,而食欲减退则与多巴胺D2受体的超敏反应有关,特别是位于穹窿周下丘脑的那些D2受体。如果是这样,在长期舒必利治疗中断后,应观察到苯丙胺和多巴胺诱导的厌食增强。测试了两种全身给药剂量的舒必利(20或200毫克/千克)和一种下丘脑内给药剂量的舒必利(15微克)。苯丙胺通过全身或下丘脑内注射给药。多巴胺在下丘脑给药。在停用全身给药的舒必利(200毫克/千克)后,观察到全身注射苯丙胺诱导的厌食增强。然而,下丘脑内注射苯丙胺或多巴胺诱导的厌食不受舒必利治疗中断的影响。这些结果表明,慢性舒必利治疗后的食欲减退并非由于下丘脑外侧多巴胺D2受体的超敏反应。此外,对苯丙胺反应的变化可能与下丘脑外D2受体的超敏反应有关。